Literature DB >> 26669207

Complete donor chimerism is a prerequisite for the effect of Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) on acute graft-versus-host disease.

Kirsten A Thus1, Roel A de Weger2, Talitha A de Hoop1, Valeria E Boers Trilles1, Jürgen Kuball1,3, Eric Spierings1.   

Abstract

Predicted indirectly recognizable HLA epitopes (PIRCHE) computationally predict donor T-cell recognition of mismatched-HLA derived peptides following allogeneic haematopoietic stem-cell transplantation (allo-HSCT), as is evidenced by the correlation between presence of HLA-DPB1-derived PIRCHE and the occurrence of graft-vs.-host disease (GVHD). Complete donor T-cell chimerism associates with an increased GVHD risk compared to mixed patient and donor chimerism. If the correlation between the presence of PIRCHE and GVHD occurrence is indeed mediated by donor T cells, the presence of donor T cells should be required to observe such a correlation. This study was initiated to investigate whether the effect of PIRCHE is different in patients with complete chimerism compared to those with mixed chimerism. Indeed, the correlation between PIRCHE and GVHD is present in patients with complete chimerism, whereas it is absent in those with mixed chimerism. The data presented here suggest that chimerism status is important for the detection of potential GVHD epitopes.

Entities:  

Keywords:  GVHD; HLA; PIRCHE; T cell; alloreactivity; chimerism

Mesh:

Substances:

Year:  2015        PMID: 26669207      PMCID: PMC5063064          DOI: 10.1080/19381956.2015.1097025

Source DB:  PubMed          Journal:  Chimerism        ISSN: 1938-1964


  19 in total

Review 1.  National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants.

Authors:  Robert A Bray; Carolyn K Hurley; Naynesh R Kamani; Ann Woolfrey; Carlheinz Müller; Stephen Spellman; Michelle Setterholm; Dennis L Confer
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

2.  T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  J Mattsson; M Uzunel; M Remberger; O Ringdén
Journal:  Transplantation       Date:  2001-02-15       Impact factor: 4.939

3.  T-cell chimerism is valuable in predicting early mortality in steroid-resistant acute graft-versus-host disease after myeloablative allogeneic cell transplantation.

Authors:  Lia Minculescu; Hans Ole Madsen; Henrik Sengeløv
Journal:  Acta Haematol       Date:  2014       Impact factor: 2.195

4.  The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation.

Authors:  T Lion; F Watzinger; S Preuner; H Kreyenberg; M Tilanus; R de Weger; J van Loon; L de Vries; H Cavé; C Acquaviva; M Lawler; M Crampe; A Serra; B Saglio; F Colnaghi; A Biondi; J J M van Dongen; M van der Burg; M Gonzalez; M Alcoceba; G Barbany; M Hermanson; E Roosnek; C Steward; J Harvey; F Frommlet; P Bader
Journal:  Leukemia       Date:  2012-03-07       Impact factor: 11.528

5.  Predicted indirectly recognizable HLA epitopes presented by HLA-DR correlate with the de novo development of donor-specific HLA IgG antibodies after kidney transplantation.

Authors:  Henny G Otten; Jorg J A Calis; Can Keşmir; Arjan D van Zuilen; Eric Spierings
Journal:  Hum Immunol       Date:  2012-12-08       Impact factor: 2.850

6.  Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT.

Authors:  D M Mickelson; L Sproat; R Dean; R Sobecks; L Rybicki; M Kalaycio; B Pohlman; J Sweetenham; S Andresen; B Bolwell; E A Copelan
Journal:  Bone Marrow Transplant       Date:  2010-03-22       Impact factor: 5.483

7.  Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease.

Authors:  Søren L Petersen; Hans O Madsen; Lars P Ryder; A Svejgaard; Tania N Masmas; Ebbe Dickmeiss; Carsten Heilmann; Lars L Vindeløv
Journal:  Biol Blood Marrow Transplant       Date:  2004-05       Impact factor: 5.742

8.  Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.

Authors:  Suzanne van Dorp; Floor Pietersma; Matthias Wölfl; Leo F Verdonck; Eefke J Petersen; Henk M Lokhorst; Edwin Martens; Matthias Theobald; Debbie van Baarle; Ellen Meijer; Jürgen Kuball
Journal:  Biol Blood Marrow Transplant       Date:  2009-04-16       Impact factor: 5.742

9.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

Review 10.  Indirectly Recognized HLA-C Mismatches and Their Potential Role in Transplant Outcome.

Authors:  Kirsten A Thus; Liane Te Boome; Jürgen Kuball; Eric Spierings
Journal:  Front Immunol       Date:  2014-05-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.